cbdMD (YCBD) Total Non-Current Liabilities (2016 - 2026)
cbdMD (YCBD) posted Total Non-Current Liabilities of $201235.0 for Q2 2025, down 49.71% sequentially from $400144.0 in Q1 2025, and down 93.2% YoY from $3.0 million in Q2 2024.
cbdMD (YCBD) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends
cbdMD has reported Total Non-Current Liabilities for 10 years, with the latest figure at $201235.0 in Q2 2025.
- Quarterly Total Non-Current Liabilities fell 93.2% year-over-year to $201235.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $201235.0 (down 93.2% YoY) and the FY2023 annual result came in at $2.5 million, down 38.91% from the prior year.
- Total Non-Current Liabilities eased to $201235.0 in Q2 2025 per YCBD's latest filing, from $400144.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $28.3 million in Q1 2021 and troughed at $201235.0 in Q2 2025.
- A 5-year average of $6.5 million and a median of $3.6 million in 2022 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2021 and 2025: Total Non-Current Liabilities surged 93.46% in 2021, then plunged 93.2% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $8.2 million in 2021, then sank by 56.11% to $3.6 million in 2022, then sank by 41.77% to $2.1 million in 2023, then sank by 71.65% to $591583.0 in 2024, then plunged by 65.98% to $201235.0 in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $201235.0, $400144.0, and $591583.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 334.00 Mn |
| 10 | cbdMD | 5.41 Mn | 3.29 Mn | 3.04 Mn | 1.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.85 Mn |
| Jun 30, 2025 | 201,235.00 |
| Mar 31, 2025 | 400,144.00 |
| Dec 31, 2024 | 591,583.00 |
| Jun 30, 2024 | 2.96 Mn |
| Mar 31, 2024 | 4.53 Mn |
| Dec 31, 2023 | 2.09 Mn |
| Sep 30, 2023 | 2.49 Mn |
| Jun 30, 2023 | 2.85 Mn |
| Mar 31, 2023 | 3.22 Mn |
| Dec 31, 2022 | 3.58 Mn |
| Sep 30, 2022 | 4.08 Mn |
| Jun 30, 2022 | 4.81 Mn |
| Mar 31, 2022 | 7.18 Mn |
| Dec 31, 2021 | 8.17 Mn |
| Sep 30, 2021 | 14.82 Mn |
| Jun 30, 2021 | 19.49 Mn |
| Mar 31, 2021 | 28.31 Mn |
| Dec 31, 2020 | 31.62 Mn |
| Sep 30, 2020 | 23.97 Mn |